Contact Us

Defective Drugs
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

   * Phone 

Cell Phone 

Name of drug: 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Dexedrine


AddThis Social Bookmark Button

Dexedrine Side Effects May Result In Heart Attack Lawsuits

Dexedrine | Lawsuits, Lawyers | Side Effects: Heart Attacks, Hallucinations, Mania

On August 21, 2006, GlaxoSmithKline announced it would add a strong warning about possible heart risk to its attention deficit hyperactivity drug (ADHD) Dexedrine. Dexedrine (Generic: Dextroamphetamine sulfate) gained FDA approval on July 9, 1997.

In March 2006, an FDA panel stated new information about heart risks should be added to the labels for attention deficit drugs. The outside experts stopped short of supporting a black box warning, the strongest warning possible saying they did not want to scare off patients or their parents. Additionally, in February 2006, a different FDA panel recommended black box warnings for all ADHD drugs.

Packaging for the drug will also contain additional information about possible psychiatric adverse events, like hallucinations and mania, linked to ADHD drugs, according to the letter dated Aug. 4, 2006.

Legal Help For Victims Affected By Dexedrine

If you or a loved one has taken Dexedrine and suffered a heart attack or any other serious side effects you may be entitled to compensation. Please fill out the form to the right, for a free case evaluation or call us at 1-800-LAW-INFO (1-800-529-4636).

DexedrineRSS Feed

ADHD Drug Study Finds Heart Death Risks for Kids, But FDA Says Recommendations Won't Change

Jun 16, 2009 | Parker Waichman LLP
While a new study has found that stimulant medications used to treat attention-deficit hyperactivity disorder (ADHD) may increase the risk of sudden cardiac death in children, the Food & Drug Administration (FDA) is not changing its recommendations on the way such drugs are prescribed.  According to a posting on its website, the agency is asserting that the study had "limitations" that makes it difficult to draw conclusions about the drugs' risks.Labeling for drugs like...
ADHD Drug Study Finds Heart Death Risks for Kids, But FDA Says Recommendations Won't Change »

FDA Directs ADHD Drug Manufacturers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse Event

Feb 21, 2007 | www.fda.gov
The U.S. Food and Drug Administration (FDA) today directed the manufacturers of all drug products approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) to develop Patient Medication Guides to alert patients to possible cardiovascular risks and risks of adverse psychiatric symptoms associated with the medicines, and to advise them of precautions that can be taken. "Medicines approved for the treatment of ADHD have real benefits for many patients but they may have...
FDA Directs ADHD Drug Manufacturers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse Event »

More Dexedrine News